Search

Your search keyword '"Rog, David"' showing total 322 results

Search Constraints

Start Over You searched for: Author "Rog, David" Remove constraint Author: "Rog, David"
322 results on '"Rog, David"'

Search Results

9. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

11. Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple Sclerosis Impact Scale (MSIS-29).

12. Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study

14. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

22. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

23. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

24. Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland.

25. Can Autonomous Sensor Systems Improve the Well-being of People Living at Home with Neurodegenerative Disorders?

26. ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK

28. Outpatient neurology diagnostic coding:a proposed scheme for standardised implementation

30. Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus

31. sj-docx-4-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus

32. sj-docx-3-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus

33. sj-docx-1-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus

34. sj-docx-2-msj-10.1177_13524585221148094 – Supplemental material for Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus

35. Measuring coping in multiple sclerosis: The Coping Index-MS

41. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

42. Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)

43. “I'm walking into the unknown': Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment

44. The impact of smoking cessation on multiple sclerosis disease progression

Catalog

Books, media, physical & digital resources